Genmab — Oktober 2025
-
Nearly half of endometrial cancer patients respond to Rina-S in trial https://rarecancernews.com/news/nearly-half-endometrial-cancer-patients-respond-rina-s-trial/
-
Investeringspodcasten: I denne uges afsnit af Investeringspodcasten dykker vi ned i Tesla-regnskabet, Genmab-faldet, Bavarian Nordic-buddet og Novo Nordisks aktieudsigter. Hør om ovenstående aktier, markedsreaktioner og meget mere i afsnit 294. https://proinvestor.com/boards/129081
-
ESMO 2025 posters via https://www.genmabmedicalaffairs.com/congress?filv1=25 - Rinatabart Sesutecan & Tisotumab Vedotin
-
Michael Novod, Nordea, går til Novo, iflg. Børsen...
-
Takeda signs deal worth up to $11.4bn with Innovent for cancer drug hopefuls -$1.2bn upfront, while Innovent will also be eligible to cash in on up to $10.2bn worth of milestone payments. https://www.pharmaceutical-technology.com/news/takeda-innovent-oncology-licensing-deal-11-4bn-adc-bispecifics/?cf-view
-
Roche presentation Q3 2025 https://assets.roche.com/f/176343/x/a22e1c7d2f/irp251023.pdf
-
Godmorgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind